The PATINA study coordinated in Italy by Fondazione Michelangelo, shows that adding palbociclib to standard therapy improves progression-free survival in hormone receptor-positive and HER2-positive metastatic breast cancer patients fondazionemichelangelo.org/news-update/... #BreastCancer #Oncology

Results from the phase 2 PRADO trial show favorable 5-years outcomes in overall survival with adjuvant ipilimumab plus nivolumab in stage III macroscopic melanoma fondazionebonadonna.org/en/neoadjuva... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Clinical benefits on disease-free survival and overall survival with the addition of carboplatin to adjuvant epirubicin/cyclophosphamide followed by taxanes in early-stage triple-negative breast cancer fondazionemichelangelo.org/news-update/... #FondazioneMichelangelo #Oncology #CancerResearch

Adding the bispecific anti-HER2 antibody anbenitamab to chemotherapy improved progression-free survival and overall survival in previously treated HER2-positive gastric cancer fondazionebonadonna.org/en/anbenitam... #FondazioneBonadonna #CancerResearch @mauriziocallari.bsky.social

Neoadjuvant intralesional darumon, a combination of two fibronectin-targeting immunocytokines, improved recurrence-free survival in patients with locally advanced melanoma fondazionebonadonna.org/en/targeted-... #FondazioneBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social

Addition of camrelizumab to neoadjuvant chemotherapy significantly improves pathological complete response rate in early or locally advanced triple-negative breast cancer fondazionebonadonna.org/en/neoadjuva... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Camrelizumab plus chemotherapy, compared to chemoradiotherapy, is a safe an effective neoadjuvant strategy in resectable esophageal squamous cell carcinoma fondazionebonadonna.org/en/camrelizu... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Addition of carboplatin to sequential taxane-anthracycline neoadjuvant therapy increased overall survival in premenopausal women with triple-negative breast cancer fondazionemichelangelo.org/news-update/... #FondazioneMichelangelo #Oncology #CancerResearch @mauriziocallari.bsky.social

A combination of nivolumab and ipilimumab is associated with a high rate of durable responses in mismatch repair–deficient/microsatellite instability–high non colorectal cancers fondazionebonadonna.org/en/a-combina... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

A promising clinical activity for the novel antibody-drug conjugate patritumab deruxtecan in non-small-cell lung cancer patients with active brain metastases fondazionebonadonna.org/en/efficacy-... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

On the occasion of World Cancer Day 2026, #FGB, with the support of the Prada Group and in collaboration with #ESO, announces the 3 winners of the fifth edition of the Fellowship named after Gianni Bonadonna. Press Release fondazionebonadonna.org/wp-content/u...) #FondazioneBonadonna #PradaGroup

A new phase 3 trial shows the non-inferiority of three versus six months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in colorectal cancer fondazionebonadonna.org/en/three-ver... #FondazioneBonadonna #Oncology #CancerResearch

In a phase 1 trial, universal base-edited CAR7 T cells induced remission in relapsed or refractory acute lymphoblastic leukemia allowing a successful stem-cell translplantation in most patients fondazionebonadonna.org/en/universal... #FondazioneBonadonna #CancerResearch @mauriziocallari.bsky.social

Sacituzumab govitecan as first-line therapy showed a significantly longer progression-free survival than chemotherapy in patients with advanced triple-negative breast cancer fondazionebonadonna.org/en/sacituzum... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Results from lidERA trial show a significant improvement in disease-free survival with the novel SERD giredestrant in HR+/HER2- early stage breast cancer fondazionebonadonna.org/en/disease-f... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

In patients with muscle-invasive bladder cancer, ctDNA-guided adjuvant therapy with atezolizumab improved disease-free survival and overall survival fondazionebonadonna.org/en/a-ctdna-g... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Results from lidERA trial show a significant improvement in disease-free survival with the novel SERD giredestrant in HR+/HER2- early stage breast cancer fondazionebonadonna.org/en/capivaser... #FondazioneGianniBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social

In a phase 3 trial the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved clinical outcome in patients with advanced head and neck cancer fondazionebonadonna.org/en/neoadjuva... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Adjiuvant abemaciclib added to endocrine therapy improves overall survival in patients with HR+/HER2- high risk early breast cancer fondazionemichelangelo.org/news-update/... #FondazioneMichelangelo #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Results from TUXEDO-3 phase 2 trial show a promising clinical activity for the novel antibody-drug conjugate patritumab deruxtecan in breast cancer patients with acrive brain metastases fondazionebonadonna.org/en/patrituma... #FondazioneBonadonna #CancerResearch @mauriziocallari.bsky.social

A new study identifies 7 tumor microenvironment types and shows how they can shape therapeutic response, recurrence and metastases development in breast cancer fondazionebonadonna.org/en/the-relev... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social #Bianchini #Criscitiello

A lot of advances have emerged from the Joint International Conference 2025 Innovation in Oncology organized by FGB with Prada Group supporting partner, by Fondazione Michelangelo and by European School of Oncology fondazionebonadonna.org/en/from-new-... #FondazioneGianniBonadonna #CancerResearch

The Godard Cinema of Fondazione Prada hosted today the opening press conference of the “Joint International Conference 2025”. The event is organized by FGB with the support of #PradaGroup #FondazioneMichelangelo and @ESOncology . fondazionebonadonna.org/wp-content/u... #CancerResearch #Oncology

mRNA vaccines targeting non-tumor-related antigens are potent immune modulators capable of sensitizing tumors to immune checkpoint blockade fondazionebonadonna.org/en/sars-cov-... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Capivasertib added to abiraterone with androgen deprivation therapy increases progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer fondazionebonadonna.org/en/capivaser... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Final overall survival data from SOLTI-1303-PATRICIA trial highlight the relevance of gene expression profiling in HER2+ breast cancer, validating the potential of non-chemotherapy approaches in selected patients fondazionemichelangelo.org/it/notizie-e... #FondazioneMichelangelo #CancerResearch

Adding radiotherapy to immunotherapy can have systemic immunomodulatory and antitumor effects and may be a way to overcome immunotherapy resistance in non-small cell lung cancer fondazionebonadonna.org/en/pembroliz... #FondazioneBonadonna #Oncology @mauriziocallari.bsky.social

A phase 2 study with the antibody-drug conjugate patritumab deruxtecan showed promising activity and manageable tolerability in patients with HR+/HER2− metastatic breast cancer fondazionebonadonna.org/en/patrituma... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Analysis of the NeoTRIP trial showed that tumor-specific MHC-II expression is associated with improved response to neoadjuvant chemo-immunotherapy in early triple negative breast cancer fondazionemichelangelo.org/news-update/... #FondazioneMichelangelo #CancerResearch @mauriziocallari.bsky.social

Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, shows a predictable safety profile and a promising antitumor activity in metastatic colorectal cancer fondazionebonadonna.org/en/the-antib... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Camizestrant in association with abemaciclib, palbociclib or ribociclib shows a well-tolerated safety profile and encouraging clinical activity in heavily pretreated advanced breast cancer fondazionebonadonna.org/en/camizestr... #Oncology #CancerResearch @mauriziocallari.bsky.social

Phost’in Therapeutics and Fondazione Gianni Bonadonna to present first clinical data on PhOx430, a First-In-Class GnT-V inhibitor, at @myesmo.bsky.social 2025. Press release fondazionebonadonna.org/wp-content/u... #PhostInTherapeutics #FondazioneBonadonna #therapeuticinnovation #CancerResearch

Respiratory viral infections can lead to loss of the pro-dormancy phenotype in disseminated #BreastCancer cells in the lung, causing proliferation and expansion of carcinoma cells within days fondazionebonadonna.org/en/metastati... #FondazioneBonadonna #Oncology @mauriziocallari.bsky.social

The ATRACTIB phase 2 trial shows clinical benefit with a combination of atezolizumab, paclitaxel and bevacizumab as first-line treatment in advanced triple-negative breast cancer fondazionebonadonna.org/en/atezolizu... #FondazioneBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social

A dual HER2-targeted blockade with neoadjuvant pyrotinib and ARX788, a new antibody-drug conjugate, as a promising strategy in early or locally advanced HER2-positive breast cancer fondazionebonadonna.org/en/pyrotinib... #FondazioneBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social

Milan to host the Joint Conference 2025 on New Drugs and the Impact of AI in Oncology, organized by FGB with the Prada Group as supporting partner, Fondazione Michelangelo and @ESOncology . Press Release fondazionebonadonna.org/area-press/ #FondazioneGianniBonadonna #FondazioneMichelangelo

SERENA-6 trial shows a longer progression-free survival with camizestrant added to a CDK4/6 inhibitor in advanced breast cancer with an ESR-1 mutation emerged during treatment fondazionemichelangelo.org/news-update/... #FondazioneBonadonna #FondazioneMichelangelo #CancerResearch #Oncology

MATTERHORN trial results show a significantly better event-free survival with perioperative durvalumab added to chemotherapy in resectable gastric or gastroesophageal junction adenocarcinoma fondazionebonadonna.org/en/periopera... #FondazioneBonadonna #CancerResearch @mauriziocallari.bsky.social

Final results from the IMpassion031 trial confirm that adding atezolizumab to neoadjuvant chemotherapy significantly improved clinical outcomes and cleared ctDNA at surgery fondazionemichelangelo.org/news-update/... #FondazioneMichelangelo #CancerResearch #Oncology

A phase 3 study shows clinical benefit for tarlatamab as second-line treatment after chemotherapy in patients with small-cell lung cancer fondazionebonadonna.org/en/longer-su... #fondazionemichelangelo #oncology #CancerResearch @mauriziocallari.bsky.social

In ER-positive, HER2-negative advanced breast cancer vepdegestrant led to significantly longer progression-free survival than fulvestrant in the subgroup with ESR1 mutations www.fondazionemichelangelo.org/news-update/... #fondazionemichelangelo #oncology #CancerResearch

Trastuzumab deruxtecan led to significantly longer overall survival than ramucirumab plus paclitaxel among patients with HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma fondazionebonadonna.org/en/trastuzum... #FondazioneBonadonna #Oncology #CancerResearch

“Online the Scientific Programme of the FGB-FM-ESO Joint International Conference 2025 “INNOVATION IN ONCOLOGY: New Drugs and the Impact of Artificial Intelligence”. Read more and register online at www.eso.net/en/what-we-d...

Adjuvant cemiplimab led to to longer disease-free survival than placebo in cutaneous squamous-cell carcinoma with a high risk for recurrence fondazionebonadonna.org/en/cemiplima... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Addition of pembrolizumab to enzalutamide and androgen deprivation therapy is not effective in metastatic hormone-sensitive prostate cancer fondazionebonadonna.org/en/pembroliz... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Sunday July 20th is the deadline for submitting applications for the “Fellowship Gianni Bonadonna” ed 25 – Read more fondazionebonadonna.org/en/fellowshi... Il 20 luglio scadono i termini per inviare la candidature per la “Fellowship Gianni Bonadonna” 25 - Leggi fondazionebonadonna.org/fellowship/

Inavosilib plus palbociclib-fulvestrant led to a significant survival benefit versus placebo plus palbociclib-fulvestrant in PIK3CA-mutated advanced breast cancer fondazionebonadonna.org/en/inavosili... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

A first-line treatment with alectinib plus bevacizumab show efficacy and safety in ALK-rearranged non-small cell lung cancer fondazionebonadonna.org/en/alectinib... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Nivolumab plus low-dose ipilimumab shows good response rate and a clinical benefit in hypermutated HER2-negative metastatic breast cancer fondazionebonadonna.org/en/nivolumab... #fondazionebonadonna #oncology #CancerResearch @mauriziocallari.bsky.social

Trastuzumab rezetecan showed robust activity with a tolerable safety profile in a neoadjuvant setting in HER2-positive breast cancer fondazionebonadonna.org/trastuzumab-... #fondazionebonadonna #Oncology #breastcancer @mauriziocallari.bsky.social